company background image
6826 logo

Shanghai Haohai Biological Technology SEHK:6826 Stock Report

Last Price

HK$31.65

Market Cap

HK$16.0b

7D

3.9%

1Y

4.8%

Updated

08 Nov, 2024

Data

Company Financials +

Shanghai Haohai Biological Technology Co., Ltd.

SEHK:6826 Stock Report

Market Cap: HK$16.0b

6826 Stock Overview

Shanghai Haohai Biological Technology Co., Ltd.

6826 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance5/6
Financial Health5/6
Dividends2/6

Shanghai Haohai Biological Technology Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Haohai Biological Technology
Historical stock prices
Current Share PriceHK$31.65
52 Week HighHK$42.95
52 Week LowHK$21.71
Beta0.76
11 Month Change-5.80%
3 Month Change8.02%
1 Year Change4.75%
33 Year Change-17.87%
5 Year Change-0.65%
Change since IPO-24.13%

Recent News & Updates

Recent updates

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Jul 25
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

May 22
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Apr 17
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Feb 12
Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Nov 14
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 28
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Mar 09
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Nov 25
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 30
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

May 08
Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Apr 19
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Mar 04
Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 03
Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Jan 10
Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Oct 08
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Jul 07
Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

May 27
Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Apr 04
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Mar 16
Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Shareholder Returns

6826HK BiotechsHK Market
7D3.9%5.2%3.9%
1Y4.8%-14.6%19.4%

Return vs Industry: 6826 exceeded the Hong Kong Biotechs industry which returned -14.6% over the past year.

Return vs Market: 6826 underperformed the Hong Kong Market which returned 19.4% over the past year.

Price Volatility

Is 6826's price volatile compared to industry and market?
6826 volatility
6826 Average Weekly Movement7.6%
Biotechs Industry Average Movement10.3%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.9%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 6826 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6826's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20072,179Jianying Wuwww.3healthcare.com

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop.

Shanghai Haohai Biological Technology Co., Ltd. Fundamentals Summary

How do Shanghai Haohai Biological Technology's earnings and revenue compare to its market cap?
6826 fundamental statistics
Market capHK$15.96b
Earnings (TTM)HK$467.69m
Revenue (TTM)HK$2.99b

15.6x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6826 income statement (TTM)
RevenueCN¥2.75b
Cost of RevenueCN¥848.86m
Gross ProfitCN¥1.90b
Other ExpensesCN¥1.47b
EarningsCN¥430.21m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.86
Gross Margin69.10%
Net Profit Margin15.66%
Debt/Equity Ratio7.0%

How did 6826 perform over the long term?

See historical performance and comparison

Dividends

2.7%

Current Dividend Yield

85%

Payout Ratio